COPENHAGEN, Denmark, December 13 /PRNewswire/ --

- Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Relapsed Diffuse Large B-Cell Lymphoma

Genmab A/S (OMX: GEN) announced today that study centers have been initiated and are ready to enroll patients in a Phase II study of ofatumumab (HuMax-CD20(R)) to evaluate treatment of relapsed Diffuse Large B-Cell Lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant. Approximately 75 patients will be enrolled in the study which is being conducted under Genmab's collaboration with GlaxoSmithKline (GSK). Genmab will receive a milestone payment of approximately DKK 87.2 million from GSK upon treatment of the first patient in the study, expected in the near future.

PLYMOUTH, England, December 13 /PRNewswire/ --

- How do you Know if you Need to Call the Vet?

- Is it Urgent?

- Can it Wait Until a Normal Working Day?

Vet Help Direct is a free, interactive, online guide to help dog, horse, cat and rabbit owners decide if they need to contact the vet, and if so, how urgently. The website helps to alleviate the 'Can it wait until the next normal working day?' dilemma when faced with an ill or injured animal at night or on a bank holiday. The site is designed and run by British vets and is the first of its kind anywhere on the internet.

COPENHAGEN, Denmark, December 13 /PRNewswire/ --

- Summary: Genmab has Announced Details of a Planned Phase II Study of Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis

Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab's collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.

SAN FRANCISCO, December 13 /PRNewswire/ --

- Italy's leading pay-TV operator renews agreement for OpenTV solutions

OpenTV Corp. (Nasdaq: OPTV), a leading provider of solutions for the delivery of advanced television and cross-platform interactive services, announced today that Sky Italia has entered into a multi-year renewal of its middleware license agreement with OpenTV. Sky Italia is Italy's premier provider of satellite television, offering a variety of programming choices to more than four million subscribers.

REHOVOT, Israel and NEW YORK, December 13 /PRNewswire/ --

- Target Diseases for This Collaboration are Diffuse Large Cell Lymphoma, Transformed Follicular Lymphoma, and Chronic Lymphocytic Leukemia

- Collaboration to Develop MicroRNA-Based Diagnostics Test, Early Detection and Prognosis.

- 43,000 People Will be Diagnosed With These Types of Cancers in 2007 in the US Alone(1)

- MicroRNAs Hold Significant Potential as Highly Sensitive and Specific Biomarkers for Hematological Cancers

- Collaboration Also Will Seek to Identify MicroRNA (miRNA) Targets for Therapeutic Applications

LONDON, December 13 /PRNewswire/ --

Marian Salzman, the world's no. 1 Trendspotter and Chief Marketing Officer at JWT Worldwide, is back for the third year along with Ann Mack, Director of Trendspotting at JWT, with their fascinating annual forecasts for 2008. Marian has previously brought us the metrosexual man, domestic divas, globesity, fortification and wiggers (white kids who want to be black).

Trends covered include Health, Travel, Home, Technology, Fashion and Beauty. (For more detailed information on the trends below and information on many others please see contact details below.)